However, due to important role of renin–angiotensin–aldosterone system and ACE2 in cardiovascular system, it is unknown whether HIF-1α inhibition can be effective strategy in COVID-19 patients, especially in those with cardiovascular diseases as highly prevalent cases among SARS-CoV2 infected patients. This evidence concerns the gene HIF1A and COVID-19.